Gönülal, M. Et Al. 2023. Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience. Clinical, Cosmetic and Investigational Dermatology , vol.16 , 3653-3659.

Gönülal, M., Balcı, D. D., & ÖZTÜRKCAN, S., (2023). Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience. Clinical, Cosmetic and Investigational Dermatology , vol.16, 3653-3659.

Gönülal, Melis, Didem Didar Balcı, And SERAP ÖZTÜRKCAN. "Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience," Clinical, Cosmetic and Investigational Dermatology , vol.16, 3653-3659, 2023

Gönülal, Melis Et Al. "Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience." Clinical, Cosmetic and Investigational Dermatology , vol.16, pp.3653-3659, 2023

Gönülal, M. Balcı, D. D. And ÖZTÜRKCAN, S. (2023) . "Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience." Clinical, Cosmetic and Investigational Dermatology , vol.16, pp.3653-3659.

@article{article, author={Melis Gönülal Et Al. }, title={Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience}, journal={Clinical, Cosmetic and Investigational Dermatology}, year=2023, pages={3653-3659} }